10:37 AM EST - Bausch Health Companies Inc. : Announced that its subsidiary, Salix Pharmaceuticals, Inc., has entered into an amendment to its existing license agreement with Alfasigma S.p.A. to initiate a late-stage clinical program to study an investigational formulation of rifaximin in patients with postoperative Crohn's disease, an area of unmet medical need. Additionally, the companies have agreed to resolve the outstanding arbitration regarding another development project for a formulation of rifaximin. Bausch Health Companies Inc.
shares T.BHC are trading up $0.19 at $30.10.
